Shares of Skye Bioscience (SKYE) and Corbus Pharmaceuticals (CRBP) are sinking after Novo Nordisk reported Phase 2 weight loss data for monlunabant, which targets type 1 cannabinoid receptors. Skye and Corbus are developing drugs that use a similar approach to monlunabant.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE: